Forte Biosciences Files 8-K on Financials

Ticker: FBRX · Form: 8-K · Filed: May 15, 2025 · CIK: 1419041

Sentiment: neutral

Topics: financial-reporting, 8-K, company-update

TL;DR

Forte Biosciences dropped an 8-K on May 15th detailing their financial condition and results.

AI Summary

Forte Biosciences, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Dallas, Texas.

Why It Matters

This 8-K filing provides an update on Forte Biosciences' financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial results are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of these results are not provided in the excerpt.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 15, 2025.

What is Forte Biosciences, Inc.'s former company name?

Forte Biosciences, Inc.'s former company name was Tocagen Inc.

Where are Forte Biosciences, Inc.'s principal executive offices located?

Forte Biosciences, Inc.'s principal executive offices are located at 3060 Pegasus Park Dr., Building 6, Dallas, Texas, 75247.

What is the SIC code for Forte Biosciences, Inc.?

The Standard Industrial Classification (SIC) code for Forte Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Forte Biosciences, Inc. (FBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing